Cognit AI

Free PoC Opportunity for Innovative Biotech Startups and Research Labs Cognit AI is offering free Proof of Concept (PoC) engagements to the first 3 partners across diverse fields, including longevity, AI-driven drug discovery, synthetic biology, epigenetics, precision medicine, diagnostics, and genomics. Utilize our AI-powered predictive models to simulate gene regulation dynamics, transcription factor activity, and chromatin accessibility to accelerate your R&D efforts. Shorten experimental cycles, streamline discoveries, and achieve breakthroughs—all without upfront costs. You have to be a startup to avail this. This is our way to pay it forward. Limited slots available—reach out to secure your spot today! #biotech #longevity #drugdiscovery #precisionmedicine #AI #syntheticbiology #genomics #research

Please report Nathaniel Brooks as a fraud account as they are falsely claiming to be the founder at Cognit.

Can someone report @Maxwell Hsiang to LinkedIn please. He has claimed that he is the founder of Cognit AI which is not true. Seems like a fake profile or a scam account.

Cognit is focused on simulating Human Cells for pre-clinical researchers for cheaper, faster target discovery and drug development. Specifically we are focused on developing models that can predict the behavior of Gene Regulatory Networks (GRNs) through various state transitions. The ambitious goal involves considering the vast complexity of the genome, the diversity of chemical treatments, potential diseases, and different system biology states, including phenotypes and nutritional conditions. Their approach also factors in the influences of epigenetic modifications, variability in gene expression profiles, microbiome interactions, and environmental conditions. By leveraging rigorous mathematical frameworks and empirical biological data, Cognit AI aims to revolutionize the understanding of GRNs and advance precision medicine. This comprehensive approach integrates the latest advancements in artificial intelligence and machine learning to create predictive models that encapsulate the behavior of GRNs at any given time and state. By doing so, Cognit AI is positioned to significantly enhance precision medicine, potentially leading to more personalized and effective treatments for a variety of diseases. Here is an article that explains the complexity at a higher level. https://lnkd.in/gsh8DnpZ

Lack of human models in pre-clinical research leads to a staggering 95% failure rate for drugs in clinical phases. Conducting "primary cell" research in wet labs is not only time-consuming and costly, but it is also often unfeasible without immortalizing the cells. Cell immortalization loses efficacy of the primary cell. Cognit revolutionizes this process by simulating primary human cells (gene regulatory networks) in-silico, allowing researchers to perform millions of experiments daily. This innovation accelerates and reduces the cost of discovering novel pharmacodynamic biomarkers at the genomic level, tackling complex diseases such as cancer, neurodegenerative disorders, coronary heart disease, and issues related to longevity. Cognit has built a frontier AI model?from ground up at the genomic level which operates across cells and species, providing a horizontal platform that enhances efficacy and reduces off-target toxicity. Think of us as the OpenAI for genomics! #ArtificialIntelligence #BioPharma #DrugDiscovery #Math #Genomics #Cancer